Share on Pinterest Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images ...

Is Semaglutide Safe for Weight Loss? Semaglutide has been shown to be effective for weight loss in several large studies. In a clinical trial published in the Journal of the ASEAN Federation of ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group (P <.0001); using on treatment data, the reductions were 16.6% vs ...

Semaglutide is not approved to treat MASH in the U.S. Pharmaceutical maker Novo Nordisk has said it plans to seek regulatory approval for its use in treating liver disease sometime this year.

The semaglutide group achieved a weight loss of 10.5% at 72 weeks compared with 2% for adults receiving placebo (estimated difference, –8.5 percentage points; 95% CI, –9.6 to –7.4; P < .001).

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which are sometimes taken off-label for weight loss.

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine , 2025; DOI: 10.1056/NEJMoa2413258 Cite This Page : ...

Oral semaglutide improves cardiometabolic risk factors more effectively than active comparators or placebo among patients with type 2 diabetes (T2D), according to results of a study published in ...

In a subgroup analysis of based on different semaglutide medications, there was an increased risk for NAION in patients who received stand-alone Ozempic (semaglutide, Novo Nordisk) (HR = 6.27; 95% ...